The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback